{"pub": "reuters", "url": "https://af.reuters.com/article/investingNews/idAFKBN1WU0VK-OZABS", "downloaded_at": "2019-10-15 09:08:09.162247+00:00", "title": "Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino", "language": "en", "text": "Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon\n\nTOKYO (Reuters) - Japan\u2019s Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.\n\nThe sale, which Takeda said in a statement is expected to close in the quarter ending March, comes as Japan\u2019s biggest drugmaker looks to trim its debt following the $59 billion purchase of Shire.\n\nTakeda gained global heft through the Shire acquisition but left it highly indebted. It has pledged to shed non-core assets while focusing on five key areas - oncology, gastroenterology, neuroscience, rare disease, and plasma-derived therapies.\n\nTakeda said it will continue to manufacture the drugs for Acino, which is backed by Avista Capital and Nordic Capital.", "description": "Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20191015&t=2&i=1441023829&w=1200&r=LYNXMPEF9E0FK-OZABS", "published_at": "2019-10-15"}